A phase I study evaluates the combination of the CDK4/6 inhibitor abemaciclib with anti-PD-1 antibody pembrolizumab for KRAS mutant, PD-L1+ patients with stage IV NSCLC (NCT02779751). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.